What Mipharm SPA does

Mipharm SPA is an Italian contract development and manufacturing organization (CDMO) headquartered in Milan that produces pharmaceutical products on behalf of multinational and small-to-medium pharmaceutical companies. Founded in 1998 as a spin-off from Novartis (originating from a 1951 Sandoz production facility), Mipharm operates an 18,000 sqm production site in Milan comprising 9,000 sqm of production areas, 9 production departments, and 18 packaging lines supporting solid oral forms (powders, granules, capsules, tablets), liquids for oral use and nasal sprays, semi-solids (creams, gels, ointments), and suppositories/ovules. The integrated platform manages over 1,000 SKUs and produced approximately 200 million units in 2023 on a combined DMX Pharma basis.

Mipharm's technology stack centers on pharmaceutical manufacturing equipment including a 600-liter IMA fluid bed granulator with full containment automation, multi-format packaging lines (blisters, vials, bottles, tubes, sachets, strips), and serialization infrastructure implemented since 2012 with aggregation capabilities serving the US, Chinese, and Russian markets. Quality and regulatory credentials are a primary differentiator: the company holds four FDA approvals (most recent inspection September 2023), AIFA, EMA, and Russian Ministry of Health certifications, with 20% of staff dedicated to quality functions.

Revenue is generated through professional-services, fee-for-service contract manufacturing agreements. The go-to-market is enterprise B2B sales-led, employing a discovery-session, needs-analysis, and execution methodology targeting pharmaceutical clients. Exports exceed 50% of turnover across more than 100 customers including various Big Pharma companies. Mipharm was acquired by Alto Partners SGR in 2022 and subsequently merged with Doppel Farmaceutici in 2024 to form DMX Pharma (Domixtar Pharmaceuticals), a combined entity with approximately €180 million pro forma turnover and 900 employees controlled equally by Trilantic Europe and Alto Capital IV.

Name

Mipharm SPA

Legal name

Mipharm S.p.A.

Website

https://mipharm.it

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

251–500 employees

Short description

Mipharm SPA is an Italian pharmaceutical CDMO headquartered in Milan that provides contract manufacturing, packaging, R&D, and clinical trial logistics to over 100 multinational and SME pharmaceutical companies across more than 50% export reach.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical contract manufacturing
• Pharmaceutical packaging services
• Clinical trial logistics
• Formulation development
• Pharmaceutical CDMO

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Pharmaceutical Manufacturing: Mipharm operates as a Contract Development and Manufacturing Organization (CDMO) generating revenue through fee-for-service manufacturing agreements with pharmaceutical clients. Revenue is derived from producing pharmaceutical products on behalf of clients, including solid oral forms, liquids, semi-solids, and suppositories. Additional revenue streams include packaging services, R&D/formulation development services, and clinical trial logistics services. The company exports over 50% of its turnover.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Mipharm SPA is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated production, packaging, R&D/formulation development, and clinical trial logistics services to pharmaceutical companies. The company manufactures solid oral forms, liquids for oral and nasal use, semi-solids, and suppositories across 18 packaging lines and 9 production departments in an 18,000 sqm Milan facility, supporting over 1,000 SKUs and serving more than 100 pharmaceutical clients globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Contract Manufacturing Contract production of pharmaceutical products in solid oral forms (powders, granules, capsules, tablets), liquids for oral use and nasal sprays, semi-solids (creams, gels, ointments), and suppositories/ovules for pharmaceutical companies (Big Pharma and SMEs).
• Pharmaceutical Packaging Secondary packaging services for pharmaceutical products in blisters (ALU-ALU, PVC-ALU, PVDC-ALU), vials, bottles, tubes, strips, and sachets, executed across 18 packaging lines.
• Pharmaceutical R&D and Formulation Development R&D services including preformulation studies, new formulation development, laboratory and pilot batch preparation, industrial scale-up, validation batches, process optimization, troubleshooting, and preparation of technical dossiers for health authority registration.
• Clinical Trial Logistics End-to-end logistics services for clinical trials, including management of the full logistics chain, preparation of active product and placebo, analytical testing of IMPs and placebo, packaging of IMPs for single-blind or double-blind randomized studies, and collection and disposal of unused materials at clinical centers.

Quantifiable outcome

• 4 FDA approvals demonstrating quality standards compliance
• +7 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Alfa Omega (acquired by Mipharm)coreStrategic or Co-development Partner · 1 January 2023Mipharm acquired Alfa Omega in 2023, expanding its capabilities into homeopathic drug manufacturing. Alfa Omega operates as a subsidiary of Mipharm, contributing to the product portfolio and therapeutic applications served by the group.
• Neopharm GentiliminorOthersNeopharm Gentili is listed among Mipharm's partner companies on the website's partner logos section. Nature of partnership is collaborative/commercial, based on mutual trust and shared objectives between multinationals and small to medium enterprises.
• Various Big Pharma and pharmaceutical company customerscoreOthersMipharm serves over 100 pharmaceutical customers including various Big Pharma companies, spread worldwide with exports over 50% of turnover. These are customer relationships for contract manufacturing and development services.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• PCI Pharma Services: Global CDMO specializing in clinical trial services, commercial packaging, and serialization. Comparable in clinical trial logistics and serialization capabilities that overlap with Mipharm's clinical trial logistics and packaging offering.
• Catalent: Global pharmaceutical CDMO with extensive softgel, oral solid, sterile, and biologics capabilities. Comparable in core solid-dose and softgel CDMO offerings but operates at far greater scale and modality breadth than Mipharm.

Direct peers

• Fareva: French-headquartered global pharmaceutical and cosmetics CDMO with broad dosage-form coverage including oral solids, liquids, sterile, and semi-solids. Comparable in full-service European CDMO positioning serving multinational pharma clients.
• Delpharm: Leading European pharmaceutical CDMO with manufacturing across multiple dosage forms including oral solids, liquids, and sterile products. Comparable in being a multi-plant European CDMO targeting Big Pharma and mid-market clients.
• Recipharm: European-headquartered pharmaceutical CDMO offering solid dose, semi-solid, and sterile manufacturing plus serialization. Comparable in being a multi-site European CDMO serving Big Pharma and SMEs across dosage forms.
• CordenPharma: European pharmaceutical CDMO offering solid dose, sterile, peptide, and API manufacturing. Comparable as a multi-site European CDMO serving global pharma clients with integrated development-to-commercial services.
• Aenova: German pharmaceutical CDMO with capabilities across solid, semi-solid, and liquid dosage forms plus softgel capsules. Comparable as a European CDMO serving Big Pharma and mid-size pharma across similar formulation categories.
• Doppel Farmaceutici: Italian pharmaceutical CDMO and former Mipharm sister-company within DMX Pharma. Comparable in therapeutic dosage forms, packaging capabilities, and Italian customer base; now combined with Mipharm into DMX Pharma.

Regional players

• BSP Pharmaceuticals: Italian pharmaceutical CDMO specializing in sterile injectable and lyophilized oncology products. Comparable as an Italian-based pharma CDMO serving multinational clients, though focused on sterile injectables rather than oral solids.
• Olon: Italian API and generics CDMO with fermentation and chemical synthesis capabilities. Comparable as an Italian pharmaceutical manufacturing partner serving global pharma, though focused on APIs rather than finished dosage forms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mipharm-s.p.a.

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mipharm SPA